AbbVie Enters Obesity Field with Gubra’s GUB014295 Licensing Deal
US pharmaceutical giant AbbVie (NYSE: ABBV) announced that it is making significant progress in the...
NYSE: ABBV
AbbVie Collaborates with Xilio Therapeutics on Tumor-Activated Immunotherapies
US pharmaceutical giant AbbVie (NYSE: ABBV) has announced a collaboration and option-to-license agreement with fellow...
AbbVie’s Emblaveo Wins FDA Approval for Complicated Intra-Abdominal Infections
US-based pharmaceutical giant AbbVie (NYSE: ABBV) announced that it has received marketing approval from the...
AbbVie Reports Strong Q4 and Full-Year 2024 Financials
US-based pharmaceutical giant AbbVie (NYSE: ABBV) has released its Q4 and full-year 2024 financial results,...
AbbVie’s 2024 Revenue Grows Despite Humira Decline, Skyrizi and Rinvoq Surge
US-based pharmaceutical giant AbbVie (NYSE: ABBV) reported its 2024 financial results on January 31, with...
AbbVie Partners with Neomorph on Molecular Glue Degraders for Oncology and Immunology
US-based pharmaceutical giant AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...
Simcere Zaiming and AbbVie Ink $1.055B License Deal for MM Drug SIM0500
China-based Simcere Pharmaceutical Group Ltd (HKG: 2096) has announced a significant strategic move through its...
AbbVie Exercises Option for Capsida’s Neurodegenerative Disease Program
US-based Capsida Biotherapeutics has announced that its partner AbbVie (NYSE: ABBV) has exercised its option...
AbbVie Acquires Roche’s Nimble Therapeutics to Boost Immunology Pipeline
US pharmaceutical company AbbVie (NYSE: ABBV) has reached an agreement to acquire Swiss pharmaceutical giant...
Huahai Pharmaceutical’s Adalimumab Biosimilar Accepted by China’s CDE for Review
On December 14th, the China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE)...
AbbVie’s Tavapadon Shows Positive Results in Phase III TEMPO-2 Study for Parkinson’s Disease
US-based pharmaceutical company AbbVie (NYSE: ABBV) has revealed positive top-line results from the pivotal Phase...
Huadong Medicine’s Elahere (Mirvetuximab Soravtansine) Approved by NMPA for Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received marketing approval...
Sichuan Huiyu Pharmaceutical’s HY-2003 Approved for Clinical Trials by China’s NMPA
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...
AbbVie’s Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment
US-based AbbVie (NYSE: ABBV) has announced the European Commission (EC) approval for its antibody drug...
AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...
AbbVie’s Allergan Aesthetics Launches Juvéderm VOLUX in China
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the official market launch of...
AbbVie Reports Q3 2024 Revenue Growth, Strength in Immunology and Neuroscience
US pharmaceutical company AbbVie (NYSE: ABBV) has announced its financial results for the third quarter...
AbbVie Inks $1.4 Billion Deal to Acquire Alzheimer’s Drug Developer Aliada Therapeutics
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a definitive agreement to acquire all...
AbbVie and Gedeon Richter Expand Partnership to Develop Novel Neuropsychiatric Targets
AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced a licensing...
AbbVie’s Vyalev Wins FDA Approval as First Subcutaneous Levodopa Therapy for Advanced Parkinson’s
AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the US, has received approval from...